You are here

  • Home
  • Archive
  • Volume 12, Issue 5
  • First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia

Article Text

Article menu
Download PDFPDF
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia

Abstract

Anthracyclines are an effective chemotherapy agent. However, very few cases of idarubicin-induced cardiomyopathy exist. Herein, we describe a case of first-dose idarubicin-related acute heart failure in a woman with a history of myelodysplastic syndrome converted to acute myeloid leukaemia.

  • cardiovascular system
  • heart failure
  • chemotherapy
  • haematology (incl blood transfusion)

https://doi.org/10.1136/bcr-2018-228149

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.